跳到正文

医疗相关 ISO 标准准备与证据整理

按指定 ISO 标准组织差距、文件与证据准备,包含医疗器械相关体系资料,实际条文需要取得正式标准。

开源精选医疗业务35 个文件50,135 Stars浏览次数 0K-Dense-AI/scientific-agent-skills MIT版本 a1043ef
开始使用

适用环境:Python 3.11+; bundled CLIs use only the standard library and bounded local JSON/Markdown files, with no network access or credentials.

输入资料
指定标准与组织当前资料 获准使用的标准及证据范围 阅读本节完整说明
交付内容
准备与差距检查资料 证据清单和待完成事项 阅读本节完整说明
  1. 获取完整包,保留配套文件的目录结构。
  2. 按照原文准备所需工具、依赖与输入资料。
  3. 阅读对应使用步骤与输入输出说明,在自己的环境中验证结果。

使用提示摘自原文,配套文件保留来源版本;实际运行条件以各包说明为准。

正文

获取原文件

assets/templates/procedures/CAPA-procedure-template.md

STATUS: DRAFT EXAMPLE — NOT APPROVED — NOT EVIDENCE OF CONFORMITY

Adapt this structure to approved processes, applicable requirements, product risk, and authorized roles. A completed template or passing script cannot establish compliance, close a CAPA, or replace RA/QA, management, legal, regulatory, auditor, or certification-body judgment.

Controlled-document metadata

Field Entry
Document ID/revision <ID> / <revision>
Owner <accountable role>
Status draft / in-review / approved
Effective date <YYYY-MM-DD after approval>
Evidence repository <controlled location>
Supersedes/change record <IDs>
Approval role Named approver Status Date Approval evidence
Process owner <name/role> pending <date> <ID>
RA/QA <name/role> pending <date> <ID>
Authorized management <name/role> pending <date> <ID>

1. Purpose and scope

  • Controlled purpose: <organization-specific statement>
  • Products, sites, processes, and records covered: <scope>
  • Interfaces: complaints, audit, suppliers, nonconformity, risk, vigilance, design/production change, validation, training, and management review.
  • Exclusions or interfaces outside this procedure: <approved rationale/evidence>

2. Roles and authority

Role Responsibility and decision authority Escalation Competence evidence Approval
CAPA system owner <entry> <entry> <ID> <ID>
CAPA owner <entry> <entry> <ID> <ID>
Independent effectiveness reviewer <entry> <entry> <ID> <ID>
RA/QA reviewer <entry> <entry> <ID> <ID>
Closure approver <entry> <entry> <ID> <ID>

3. CAPA intake and decision

Define controlled inputs and the approved criteria for opening, escalating, linking, combining, or declining a CAPA. Do not use an arbitrary priority label as a substitute for product/process risk and reportability review.

Input Owner Decision method Evidence Status Approval
Complaint/feedback <role> <method> <ID> draft <ID>
Audit/nonconformity <role> <method> <ID> draft <ID>
Supplier issue <role> <method> <ID> draft <ID>
Trend/risk/postmarket signal <role> <method> <ID> draft <ID>

Each decision record must include:

  • unique CAPA ID and source-event links;
  • factual problem statement and known scope;
  • correction/containment and evidence;
  • product, patient/user, process, and regulatory/reportability impact review;
  • decision owner, status, rationale, evidence, and approval.

4. Investigation and systemic extent

The record must define the method before drawing a conclusion and preserve the evidence reviewed.

Field Required entry
Investigation owner/status <role> / draft
Scope and plan <entry>
Data and evidence IDs <IDs>
Analysis method and rationale <entry>
Root cause or justified conclusion <entry>
Similar/systemic issue review <entry>
Risk-file/design/supplier/process impacts <entry>
Reviewer and approval evidence <role/ID>

Do not force a preferred root-cause method. Select and approve a method appropriate to the evidence, complexity, and risk.

5. Action planning and change control

Action ID Description Owner Due date Change/validation/training links Implementation evidence Status Approval
<ID> <entry> <role> <date> <IDs> <IDs> planned <ID>

Actions must address the supported cause or risk, include objective acceptance criteria, and route affected documents, software, validation, suppliers, products, training, risk files, and postmarket controls through approved change control.

6. Effectiveness plan and review

Define the effectiveness plan before closure.

Field Required entry
Effectiveness owner <role>
Independent reviewer <role>
Objective acceptance criteria <measurable criteria>
Baseline/comparator <entry>
Data source and evidence IDs <IDs>
Sample or observation window <risk-based rationale>
Review date <YYYY-MM-DD>
Result pending / effective / ineffective
Conclusion and evidence <entry/IDs>
Approval <approver/date/record ID>

Fail-closed gate: pending, insufficient data, or ineffective cannot support closure. Re-open the investigation/action cycle or document authorized escalation.

7. Closure, cancellation, and extension

Closure requires:

  • all actions implemented with evidence;
  • approved effectiveness result of effective;
  • linked risk, design, production, supplier, postmarket, document, validation, and training changes completed or explicitly dispositioned;
  • complete source/version references;
  • closure summary, date, owner, status, evidence, and authorized approval.

Cancellation or due-date changes require a documented rationale, risk/reportability impact review, owner, status, evidence, and approval. Neither changes the need for immediate safety or regulatory action when applicable.

8. Records, metrics, and management visibility

Record/measure Owner Retention basis Location Review method Evidence Approval
CAPA record set <role> <approved basis> <location> <method> <ID> <ID>
Aging/overdue status <role> <basis> <location> <method> <ID> <ID>
Recurrence/effectiveness trend <role> <basis> <location> <method> <ID> <ID>
Management-review input <role> <basis> <location> <method> <ID> <ID>

Release checklist

  • Placeholders are resolved.
  • Interfaces to risk, complaints/vigilance, suppliers, design, production, validation, software, training, and change control are explicit.
  • No fixed timeline is used without an approved risk/process basis.
  • Effectiveness criteria are objective and approved before closure.
  • Records carry owner, status, evidence, source/version, and approval fields.
  • Authorized human approvers released the procedure.
  • The procedure makes no compliance or certification claim.

CONTACT HAONAN

联系haonan

医疗 AI · 产品与独立开发

刘浩南

关注医疗 AI 从 demo 到真实落地,聚焦产品化、商业化与院内工作流效率提升。

12年医疗产研经验,大湾区头部医疗AI公司前产品总监,独立开发者

医疗 AI 产品化医疗 AI 商业化院内工作流效率
刘浩南的微信联系二维码
微信扫一扫,联系 haonan